Find policies, billing codes, payers, states, and providers
CPT 46900: Chemical Destruction of Anal Lesion
CPT code 46900 represents a simple chemical destruction procedure for anal lesions such as condyloma, papilloma, molluscum contagiosum, or herpetic vesicles. This minor dermatologic/proctologic intervention is commonly performed in outpatient clinic or office procedural settings and is relevant to clinicians, billing professionals, and payers because correct coding affects claims adjudication and clinical documentation requirements nationwide.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on the clinical indication and typical setting for use of CPT code 46900, a synthesis of common billing and documentation considerations, and benchmarks where available. The summary highlights typical use cases and what to expect in payer coverage patterns for minor anal lesion destruction.
The publication provides practical reference material: an explanation of the code definition, service type and site-of-service implications, payer coverage landscape, and related billing considerations. Data not available in the input is noted when applicable, and the material is presented for a national audience without state-specific guidance.
Customize your policy alerts
Sign up for cpt 46900 policy alerts
Get alerted when payer policies referencing 46900 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 46900 describes a simple chemical destruction of an anal lesion, such as a condyloma, papilloma, molluscum contagiosum, or herpetic vesicle. The procedure involves application of a chemical agent to ablate superficial lesions in the anal region.
Service type: Procedure — minor cutaneous/dermatologic lesion destruction
Typical site of service: Outpatient clinic or office-based procedure room, including dermatology, proctology, or primary care settings where minor operative procedures are performed.